Recent Updates
Recently added Catalysts
LXRX Positive Sentiment

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: Lexicon Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be accessible live and via replay on the company's website. Lexicon is known for its pioneering medicines and has a strong pipeline in various therapeutic areas.
Price reaction · baseline $1.14 (2026-01-06 close) · hit pre-market · 2 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexicon Pharmaceuticals is actively engaging in key industry events.
  • The company has a robust pipeline of promising drug candidates.
  • Lexicon's innovative approach to genomics is noteworthy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) --Lexicon Pharmaceuticals, Inc.(Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco.
The live event and replay of the presentations can be accessed via the Events page of the Company’s website athttps://investors.lexpharma.com/.
About Lexicon PharmaceuticalsLexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visitwww.lexpharma.com.For Investor and Media Inquiries:Lisa DeFrancescoLexicon Pharmaceuticals, Inc.lexinvest@lexpharma.com

Frequently Asked Questions

When will Lexicon Pharmaceuticals present?

Lexicon Pharmaceuticals will present on January 15, 2026, at 12:00 p.m. PT.

Where can I access the presentation?

The presentation can be accessed via the Events page on Lexicon's website.

What is Lexicon's mission?

Lexicon aims to pioneer medicines that transform patients' lives.

What therapeutic areas does Lexicon focus on?

Lexicon focuses on heart failure, neuropathic pain, obesity, and diabetes.

Last updated: Jan 7, 2026